Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients

详细信息    查看全文

• 作者：Peter R. Breggin
• 关键词：Psychopharmacology ; Psychiatric drugs ; Adverse psychiatric drug effects ; Psychosocial alternatives to psychiatric drugs ; Ineffectiveness of psychiatric drugs ; Critical analysis of psychiatric medication
• 刊名：Journal of Contemporary Psychotherapy
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：46
• 期：1
• 页码：1-13
• 全文大小：484 KB
• 参考文献：Abramson, J. (2005). Overdo$ed America. New York: Harper Perennial.
  Adderall XR (2015, April). Full Prescribing Information. Retrieved April 11, 2015 from http://​pi.​shirecontent.​com/​PI/​PDFs/​AdderallXR_​USA_​ENG.​PDF .
  Adityanjee., Munshi, K. R., & Thampy, A. (2005). The syndrome of irreversible lithium-effectuated neurotoxicity. Clinical neuropharmacology, 28(1), 38–49.PubMed CrossRef
  American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders, fifth edition (DSM-V). Washington, DC: American Psychiatric Association.
  Angell, M. (2004). The truth about drug companies: How they deceive us and what to do about it. New York: Harper Random House.
  Antonuccio, D., Danton, W., DeNelsky, G., Greenberg, R., & Gordon, J. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68, 3–14.PubMed CrossRef
  Ballenger, J. (1995). Benzodiazepines. In A. Schatzberg & C. Nemeroff (Eds.), The American Psychiatric Press textbook of psychopharmacology (pp. 215–230). Washington, DC: American Psychiatric Press.
  Barnhart, W., Makela, E., & Latocha, M. (2004). SSRI-induced apathy syndrome: A clinical review. Journal of Psychiatric Practice, 10, 196–199.PubMed CrossRef
  Baughman, F, Jr, & Hovey, C. (2006). The ADHD Fraud: How psychiatry makes “patients” of normal children. Victoria, BC: Trafford Publishing.
  Bockoven, S. (1963). Moral treatment in American psychiatry. New York: Springer Publishing Company.CrossRef
  Breggin, P. (1980). Brain-disabling therapies. In E. Valenstein (Ed.), The psychosurgery debate: Scientific, legal and ethical perspectives (pp. 467–505). San Francisco: Freeman.
  Breggin, P. (1983). Psychiatric drugs: Hazards to the brain. New York: Springer.
  Breggin, P. (1990). Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptic drugs: Evidence, etiology, implications. Journal of Mind and Behavior, 11, 425–464.
  Breggin, P. (1991). Toxic Psychiatry: Why therapy, empathy and love must replace the drugs, electroshock, and biochemical theories of the ‘new psychiatry’. New York: St. Martin’s Press.
  Breggin, P. (1993). Parallels between neuroleptic effects and lethargic encephalitis: The production of dyskinesias and cognitive disorders. Brain and Cognition, 23, 8–27.PubMed CrossRef
  Breggin, P. (1998). Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA’s spontaneous reporting system. Journal of Mind and Behavior, 19, 21–50.
  Breggin, P. (1999). Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action. International Journal of Risk and Safety in Medicine, 12, 3–35.
  Breggin, P. (2003/2004). Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. International Journal of Risk and Safety in Medicine, 16, 31–49.
  Breggin, P. (2007). Intoxication anosognosia: The spellbinding effect of psychiatric drugs. International Journal of Risk and Safety and Medicine, 19, 3–15.
  Breggin, P. (2008a). Brain-disabling treatments in psychiatry: Drugs, electroshock, and the psychopharmaceutical complex (2nd ed.). New York: Springer.
  Breggin, P. (2008b). Medication madness: The role of psychiatric drugs in cases of violence, suicide, and crime. New York: St. Martin’s Press.
  Breggin, P. (2011). Psychiatric drug-induced chronic brain impairment (CBI): Implications for long-term treatment with psychiatric medication. International Journal of Risk & Safety in Medicine, 23(4), 193–200.
  Breggin, P. (2013). Psychiatric drug withdrawal: A guide for prescribers, therapists, patients and their families. New York: Springer.
  Breggin, P. (2014a). The rights of children and parents in regard to children receiving psychiatric drugs. Children and Society, 28, 231–241.CrossRef
  Breggin, P. (2014b). Guilt, shame and anxiety: Understanding and overcoming negative emotions. Amherst, NY: Perseus Books.
  Breggin, P. (2015). The biological evolution of guilt, shame and anxiety: A new theory of negative emotions. Medical Hypotheses. doi:10.​1016/​j.​mehy.​2015.​03.​015 .PubMed
  Breggin, P., & Breggin, G. (2004). Talking back to Prozac. New York: St. Martin’s Press.
  Cade, J. (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia, 2(36), 349–352.PubMed
  Caplan, P. (1996). They say you’re crazy: How the world’s most powerful psychiatrists decide who’s normal. New York: De Capo Press.
  Caplan, P. (2015). Diagnosisgate: Conflict of interest at the top of the psychiatric apparatus. Aporia, 7(1). Retrieved May 3, 2015 from http://​www.​madinamerica.​com/​2015/​03/​revisiting-tmap-scandal-j-j-paid-allen-frances-develop-schizophrenia-guidelines/​ .
  Corrigan, M. W. (2012). Handbook of prosocial education. Lanham, MD: Roman and Littlefield.
  Corrigan, M. W. (2014). Debunking ADHD: 10 reasons to stop drugging kids for acting like kids. Lanham, MD: Roman and Littlefield.
  Cosgrove, L. (2010). Diagnosing conflict-of-interest disorder: Big Pharma works in subtle but powerful ways inside the pages of the Diagnostic and Statistical Manual of Mental Disorders. AAUP (American Association of University Professors). Retrieved May 1, 2015 from http://​www.​aaup.​org/​article/​diagnosing-conflict-interest-disorder#.​VUQf-5N4YmQ .
  Cosgrove, L., Krimsky, S., Vijayaraghavan, M., & Schneider, L. (2006). Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics, 76, 154–160.CrossRef
  Csoska, A., & Shipko, S. (2006). Persistent sexual side effects after SSRI discontinuation. Psychotherapy and Psychosomatics, 75, 187–188.CrossRef
  Cuijpers, P., Berking, M., Andersson, G., et al. (2013a). A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Canadian Journal of Psychiatry, 58(7), 376–385.
  Cuijpers, P., Donker, T., van Straten, A., & Andersson, G. (2010). Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychological Medicine, 40, 1943–1957.PubMed CrossRef
  Cuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., et al. (2013b). The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: A meta-analysis of direct comparisons. World Psychiatry, 12, 137–148.PubMed PubMedCentral CrossRef
  Decker, H. (2013). The Making of DSM-III ® : A diagnostic manual’s conquest of American psychiatry. New York: Oxford University Press.
  Deniker, P. (1970). Introduction of neuroleptic chemotherapy into psychiatry. In F. Ayde & B. Blackwell (Eds.), Discoveries in biological psychiatry (pp. 155–164). Philadelphia: Lippincott.
  El-Mallakh, R., Gao, Y., & Roberts, J. (2011). Tardive dysphoria: The role of long term antidepressant use in inducing chronic depression. Medical Hypotheses, 76, 769–773.PubMed CrossRef
  Frances, A. (2014). Saving normal: An insider’s revolt against out-of-control psychiatric diagnosis: DSM-5, Big Pharma, and the Medicalization of Ordinary Life. New York: William Morrow.
  Gitlin, M., Swendsen, J., Heller, T., & Hammen, C. (1995). Relapse and impairment in bipolar disorder. American Journal of Psychiatry, 152, 1635–1640.PubMed CrossRef
  Glenmullen, J. (2000). Prozac backlash. New York: Simon & Schuster.
  Gøtzsche, P. C. (2013). Deadly medicines and organised crime: How big pharma has corrupted healthcare. London: Radcliffe Medical Press.
  Gøtzsche, P. C. (2015). Deadly psychiatry and organised denial. Copenhagen: People’s Press.
  Grahame-Smith, D. G., & Aronson, J. K. (1992). Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press.
  Harrow, M., & Jobe, T. (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A fifteen year multifollow-up study. Journal of Nervous and Mental Disease, 195, 406–414.PubMed
  Healy, D. (2015). Serotonin and depression: The marketing of a myth. BMJ, 350, h1771. doi:10.​1136/​bmj.​h1771 .PubMed CrossRef
  Insel, T. (2011, December). Director’s Blog: Antidepressants: A complicated picture. Retrieved on May 1, 2015 from http://​www.​nimh.​nih.​gov/​about/​director/​2011/​antidepressants-a-complicated-picture.​shtml .
  Janssen Pharmaceuticals, Inc. (2014). Risperdal Complete Prescribing Information. Retrieved on May 1, 2015 from http://​www.​janssenpharmaceu​ticalsinc.​com by Googling “Risperdal Full Prescribing Information”.
  Janssen Research Foundation. (1992a, February). An integrated summary of the effectiveness of risperidone. (R 64,766). Original New Drug Application (NDA). Obtained from FDA through Freedom of Information.
  Janssen Research Foundation. (1992b, March). Integrated summary of information on the safety of risperidone. (R 64,766). Original New Drug Application (NDA). Obtained from FDA through Freedom of Information.
  Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry, 188, 122–127.PubMed CrossRef
  Karon, B. (2003). The tragedy of schizophrenia without psychotherapy. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 331, 89–118.CrossRef
  Karon, B. (2005). Recurrent psychotic depression is treatable by psychoanalytic therapy without medication. Ethical Human Psychology and Psychiatry, 7, 45–56.
  Karon, B., & Vandenbos, G. (1981). The psychotherapy of schizophrenia: The treatment of choice. New York: Aronson.
  Kirsch, I. (2010). The emperor’s new drugs: Exploding the antidepressant myth. New York: Basic Books.
  Kirsch, I., Deacon, B. J., Huedo-Median, T., Scoboria, A., Moore, T., & Johnson, B. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45.PubMed PubMedCentral CrossRef
  Kutchins, H., & Kirk, S. (2003). Making Us Crazy: DSM: The Psychiatric Bible and the creation of mental disorders. New York: Free Press.
  Lacasse, J. R., & Leo, J. (2005). Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med, 2(12), e392.PubMed PubMedCentral CrossRef
  Lagace, D. C., & Eisch, A. J. (2005). Mood-stabilizing drugs: Are their neuroprotective aspects clinically relevant? The Psychiatric Clinics of North America, 28(2), 399–414.PubMed CrossRef
  Leber, P. (1992). Postmarketing surveillance of adverse drug effects. In J. Kane & J. Lieberman (Eds.), Adverse effects of psychotropic drugs (pp. 3–12). New York: Guilford.
  Lehmann, H. E., & Hanrahan, G. C. (1954). Chlorpromazine, a new inhibiting agent for psychomotor excitement and manic states. Archives of Neurology and Psychiatry, 71, 227–237.PubMed CrossRef
  Lieberman, J., & Stroup, T. (2011). The NIMH-CATIE schizophrenia study: What did we learn? American Journal of Psychiatry, 168, 770–775.PubMed CrossRef
  Lieberman, J., Stroup, T., McEvoy, J., Swartz, M., Rosenheck, R., Perkins, D., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.PubMed CrossRef
  Madsen, T., Treschow, A., Bengzon, J., Bolwig, T., Lindvall, O., & Tingstrom, A. (2000). Increased neurogenesis is a model of electroconvulsive therapy. Biological Psychiatry, 47, 1043–1049.PubMed CrossRef
  Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. The Journal of Neuroscience, 20(24), 9104–9110.PubMed
  Marangell, L., Silver, J., Goff, D., & Yudofsky, S. (2003). Pharmacology and electroconvulsive therapy. In R. Hales & S. Yudofsky (Eds.), The American Psychiatric Publishing textbook of clinical psychiatry (4th ed., pp. 1047–1149). Washington, DC: American Psychiatric Press.
  Marks, I. M., De Albuquerque, A., Cottraux, J., Gentil, V., Greist, J., Hand, I., et al. (1989). The ‘efficacy’ of alprazolam in panic disorder and agoraphobia: A critique of recent reports. Archives of General Psychiatry, 46(7), 668–670.
  Miller, R. (2009). Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. Current Neuropharmacology, 7, 315–330.PubMed PubMedCentral CrossRef
  Moncrieff, J. (2007a). The myth of the chemical cure: A critique of psychiatric drug treatment. Hampshire: Palgrave Macmillan.CrossRef
  Moncrieff, J. (2007b). Understanding psychotropic drug action: The contribution of the brain-disabling theory. Ethical Human Psychology and Psychiatry, 9, 170–179.CrossRef
  Moncrieff, J. (2013). The bitterest pills: The troubling story of antipsychotic drugs. New York: Palgrave.CrossRef
  Morrison, A., Hutton, P., Wardle, M., Spencer, H., Barratt, S., Brabban, A., et al. (2012). Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: An exploratory trial. Psychological Medicine, 42, 1049–1056.PubMed CrossRef
  Morrison, A., Turkington, D., Pyle, M., Spencer, H., Brabban, A., Dunn, G., et al. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomized controlled trial. Lancet, 383, 1395–1403.PubMed CrossRef
  Mosher, L. (1996). Soteria: A therapeutic community for psychotic patients. In P. Breggin & E. Stern (Eds.), Psychosocial approaches to deeply disturbed persons (pp. 43–58). New York: Haworth Press.
  Mosher, L., & Bola, J. (2004). Soteria-California and its American Successors: Therapeutic ingredients. Ethical Human Psychology and Psychiatry, 6, 7–23.
  Myslobodsky, M. S. (1993). Central determinants of attention and mood disorder in tardive dyskinesia ("tardive dysmentia"). Brain and Cognition, 23(1), 88–101.PubMed CrossRef
  Myslobodsky, M. S., Tomer, R., Holden, T., Kempler, S., & Sigal, M. (1985). Cognitive impairment in patients with tardive dyskinesia. The Journal of Nervous and Mental Disease, 173(3), 156–160.PubMed CrossRef
  Neal, M., Gardner, C., Halberstadt, L., Kornstein, S., & Andrew, P. (2011). Blue again: Perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Frontiers in Psychology, 2011(2), 2011. doi:10.​3389/​fpsy.​g.​2011.​00159 .
  Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., et al. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? International Journal of Neuropsychopharmacology, 5(2), 147–151.
  Orser, B. (2007, June). Lifting the fog around anesthesia. Scientific American, pp. 54–59.
  Pachter, W., Fox, R., Zimbardo, P., & Antonuccio, D. (2007). Corporate funding and conflicts of interest: A primer for psychologists. American Psychologist, 62(9), 1005–1015.PubMed CrossRef
  Parent, Jack. (2003). Injury-induced neurogenesis in the adult mammalian brain. The Neuroscientist, 9(4), 261–272.PubMed CrossRef
  Perlis, R., Ostacher, M., Patel, J., Marangell, L., Zhang, H., Wisniewski, S., et al. (2006). Predictors of recurrent in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry, 163, 217–224.PubMed CrossRef
  Pies, R. (2011, July 11). Psychiatry’s new brain-mind and the legend of the “chemical imbalance.” Psychiatric Times. Retrieved on May 1, 2015 from http://​www.​psychiatrictimes​.​com/​blogs/​couch-crisis/​psychiatry-new
  ain-mind-and-legend-chemical-imbalance .
  Pigott, H. (2011). STAR*D: A tale and trail of bias. Ethical Human Psychology and Psychiatry, 13, 6–28.CrossRef
  Pigott, H., Leventhal, A., Alter, G., & Boren, J. (2011). Efficacy and effectiveness of antidepressants: Current status of research. Psychotherapy and Psychosomatics, 79, 267–279.CrossRef
  Podrabinek, A. (1979). Punitive medicine. In H. Fireside (Ed.), Soviet psychoprisons. New York: Norton.
  Randrup, A., & Munkva, I. (1967). Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia, 11, 300–310.PubMed CrossRef
  Read, M. (2002, March 12). Long acting neuroleptic drugs. In D. Heard (Ed.), Zoological Restraint and Anesthesia. International Veterinary Information Service (www.​ivis.​org ), Ithaca, New York. Retrieved on October 25, 2011 from http://​www.​ivis.​org/​special_​books/​Heard/​read/​IVIS.​pdf .
  Rothman, D. J. (2010). Expert Report [For the Texas Attorney General’s Office against Johnson and Johnson, and its subsidiary Janssen, the manufacturer of Risperdal]. Unpublished. Retrieved on May 3, 2015 from http://​psychrights.​org/​States/​Texas/​exrelJonesvJanss​en/​David_​Rothman_​Expert_​Report_​300dpi.​pdf .
  Schiorring, E. (1977). Changes in individual and social behavior induced by amphetamines and related compounds in monkeys and man. In E. H. Ellinwood Jr & M. M. Kilbey (Eds.), Cocaine and other stimulants (pp. 481–522). New York: Plenum.CrossRef
  Schiorring, E. (1979). Social isolation and other behavioral changes in groups of adult vervet monkeys (Cercopithecus aethiops) produced by low, nonchronic doses of d-amphetamine. Psychopharmacology (Berl), 64, 297–302.CrossRef
  Seikkula, J., Aaltonen, J., Alakare, L., Haarakangas, K., Keranen, J., & Lehtinen, K. (2006). Five-year experience of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychotherapy Research, 16, 214–228.CrossRef
  Seikkula, J., Alakare, B., Aaltonen, J., Holma, J., Rasinkangas, A., & Lehtinen, V. (2003). Open dialogue approach: Treatment principles and preliminary results of a two-year follow-up of first episode schizophrenia. Ethical Human Sciences and Services, 5(3), 163–182.
  Swanson, J., Elliott, G., Greenhill, L., Wigal, T., Arnold, L., Vitiello, B., et al. (2007a). Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1015–1027.PubMed CrossRef
  Swanson, J., Hinshaw, S., Arnold, L., Gibbons, R., Marcus, S., Hur, K., et al. (2007b). Second evaluation of MTA 36-month outcomes: Propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 989–1002.PubMed CrossRef
  Tuke, S. (1996). Description of the retreat. London: Process Press.
  University of Rochester Medical Center (2011). Anti-depressants boost brain cells after injury in early studies. Retrieved April 11, 2015 from http://​www.​urmc.​rochester.​edu/​news/​story/​index.​cfm?​id=​3173 .
  Wang, C., Zhang, M., Sun, C., Cai, Y., You, Y., Huang, L., & Liu, F. (2011). Sustained increase in adult neurogenesis in the rat hippocampal dentate gyrus after transient brain ischemia. Neuroscience Letters, 28, 70–75.
  Watters, E. (2011). Crazy like us: The globalization of the American psyche. New York: Free Press.
  Weiss, M., Murray, C., Wasdell, M., Greenfield, B., Giles, L., & Hechtman, L. (2012). A randomized controlled trial of CBT therapy for adults with ADHD with and without medication. BMC Psychiatry, 12, 30.PubMed PubMedCentral CrossRef
  Whitaker, R. (2002). Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. New York: Perseus.
  Whitaker, R. (2010). Anatomy of an epidemic: Magic bullets, psychiatric drugs, and the astonishing rise of the mental illness in America. New York: Crown Publishers.
  Whitaker, R., & Cosgrove, L. (2015). Psychiatry under the influence: Institutional corruption, social injury, and prescriptions for reform. New York: Palgrave Macmillan.CrossRef
  Wilson, D., & Singer, N. (2009, September 11). Ghostwriting is called rife in medical Journals. New York Times. Retrieved April 5, 2015 from http://​www.​nytimes.​com/​2009/​09/​11/​business/​11ghost.​html?​_​r=​0 .
  XANAX® XR CIV (alprazolam) extended-release tablets (2011). (Complete Prescribing Information, 22 pages). (2011, March). Retrieved August 31, 2011 from http://​labeling.​pfizer.​com/​ShowLabeling.​aspx?​id=​543 .
  
• 作者单位：Peter R. Breggin (1)
  
  1. Center for the Study of Empathic Therapy, 101 East State St #112, Ithaca, NY, 14850, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Public Health
  Psychiatry
  Clinical Psychology
  Personality and Social Psychology
  
• 出版者：Springer Netherlands
• ISSN：1573-3564

文摘

Because the epidemic dispensing of psychiatric drugs is based on misinformation, it is important for all health professionals, consumers, and most citizens (including patients and their family members) to have a more rational understanding of how psychiatric drugs actually “work.” Instead of enforcing authoritarian “medication compliance” in obedience to the prescriber’s orders, informed therapists and healthcare providers have an ethical duty to provide scientific information about the real effects of psychiatric drugs. Instead of naively accepting whatever the doctor prescribes to them, consumers need to educate themselves about all medications, but especially about psychiatric ones, which are consistently misrepresented and oversold. This review focuses on three principles of rational psychopharmacology. The first is the brain-disabling principle, which states that all psychoactive substances work by causing dysfunctions of the brain and mind. It further observes that no psychiatric drugs work by improving or correcting biochemical imbalances or any other presumed biological malfunctions. The second principle is intoxication anosognosia (medication spellbinding) which states that all psychoactive substances tend to cause a subjective over-estimation of their positive effects while masking their harmful ones, sometimes resulting in extremely harmful behaviors such as mania, violence and suicide. The third principle is chronic brain impairment (CBI)—that exposure to psychoactive substances, especially long-term, results in impairments of the brain or mind that can become persistent or permanent, including atrophy (shrinkage) of brain tissue. Not only are psychiatric drugs likely to do more harm than good, there are more effective and infinitely safer proven psychosocial approaches for treating the whole spectrum of “psychiatric disorders” from “ADHD” and “major depressive disorder” to “schizophrenia.”

Keywords Psychopharmacology Psychiatric drugs Adverse psychiatric drug effects Psychosocial alternatives to psychiatric drugs Ineffectiveness of psychiatric drugs Critical analysis of psychiatric medication